Skip to main content
Premium Trial:

Request an Annual Quote

RXi Inks Deal to Sell Anti-scarring Drug in EU Prior to Approval


RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.

According to RXi, Ethicor will be able to supply the drug before it receives regulatory clearance under EU legislation that allows authorized health care professionals to administer such agents to individual special-needs patients under their care. The unapproved drug may not be marketed to doctors, however.

Under the terms of their deal, RXi and Ethicor will share the sales from RXI-109. Once the drug receives regulatory approval, RXi will regain the marketing rights to the drug.